Podcasts about Supreme

Welcome to What Matters Now, a weekly podcast exploring key issues currently shaping Israel and the Jewish World, with host Amanda Borschel-Dan speaking with author and public intellectual Micah Goodman. Just ahead of this week's What Matters Now recording, Prime Minister Benjamin Netanyahu and US President Donald Trump sat in the White House for a celebratory meal. The table was set for a grand announcement -- a sealed hostage release-ceasefire deal -- but the guest of honor and his terrorist counterparts have yet to come to terms. Goodman looks back at the two huge "double gambles" made during these 21 months of war. The first was by former Hamas leader Yahye Sinwar, who launched the invasion of Israel on October 7, 2023, after viewing the intense divisiveness in Israeli society. His double-or-nothing bet was that Iran and its proxies would immediately join in the onslaught -- they didn't. Goodman compares Sinwar's double gamble to that of Netanyahu, who launched a surprise preemptive strike on Iran's nuclear program on June 13 and wagered that the United States would join. Now that Netanyahu's bet has paid off, Goodman describes how the region is ripe for a realignment -- if tough compromises can be made to end the Gaza war. And so this week, we ask Micah Goodman, what matters now. What Matters Now podcasts are available for download on Apple Podcasts, Spotify, YouTube or wherever you get your podcasts. This episode was produced by the Pod-Waves and video edited by Thomas Girsch. IMAGE: Shiite Muslim mourners hold portraits of Iran's Supreme leader Ayatollah Ali Khamenei during a religious procession held to mark Ashura, on the 10th day of the Islamic holy month of Muharram in Karachi on July 6, 2025. (Asif HASSAN / AFP)See omnystudio.com/listener for privacy information.

In the 80s and 90s, New York City's skateboarding scene was wild and gritty, and seemingly unable to be commercialized. And then the streetwear brand Supreme came along. Director Josh Swade discusses the new 30 for 30 documentary “Empire Skate,” which tells the story of 1990s New York City skate culture that inspired a global brand.

Joyce discusses Washington Politics and how no one can be trusted, President Biden's doctor pleading the 5th in his health cover up, the Epstein files have disappeared with some saying they never existed. Legal Expert Hans von Spakovsky from the Heritage Foundation joins the show to talk Supreme court decisions, Trump legal victories, illegal immigration and election changes. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to What Matters Now, a weekly podcast exploring key issues currently shaping Israel and the Jewish World, with host Amanda Borschel-Dan speaking with author and public intellectual Micah Goodman. Just ahead of this week's What Matters Now recording, Prime Minister Benjamin Netanyahu and US President Donald Trump sat in the White House for a celebratory meal. The table was set for a grand announcement -- a sealed hostage release-ceasefire deal -- but the guest of honor and his terrorist counterparts have yet to come to terms. Goodman looks back at the two huge "double gambles" made during these 21 months of war. The first was by former Hamas leader Yahye Sinwar, who launched the invasion of Israel on October 7, 2023, after viewing the intense divisiveness in Israeli society. His double-or-nothing bet was that Iran and its proxies would immediately join in the onslaught -- they didn't. Goodman compares Sinwar's double gamble to that of Netanyahu, who launched a surprise preemptive strike on Iran's nuclear program on June 13 and wagered that the United States would join. Now that Netanyahu's bet has paid off, Goodman describes how the region is ripe for a realignment -- if tough compromises can be made to end the Gaza war. And so this week, we ask Micah Goodman, what matters now. What Matters Now podcasts are available for download on Apple Podcasts, Spotify, YouTube or wherever you get your podcasts. This episode was produced by the Pod-Waves and video edited by Thomas Girsch. IMAGE: Shiite Muslim mourners hold portraits of Iran's Supreme leader Ayatollah Ali Khamenei during a religious procession held to mark Ashura, on the 10th day of the Islamic holy month of Muharram in Karachi on July 6, 2025. (Asif HASSAN / AFP)See omnystudio.com/listener for privacy information.

Multi-million dollar rideshare company Uber took it's fight over drivers employment rights to the Supreme court today. The Court is deciding whether it's drivers should be considered employees. This could give the drivers benefits such as leave entitlements, minimum wage and holiday pay. Bill Hickman reports.

7-7 Dirty Work Hour 2: Joey Chestnut reigns supreme & the latest on a potential GS-SAC Kuminga tradeSee omnystudio.com/listener for privacy information.

In this episode, I go over a list of 12 Origin Theories of Freemasonry and ask the Curmudgeon Supreme how much he knows about any of these theories. This list was found in a book called the Royal Masonic Cyclopedia.Has he ever heard of any of these?Does he have a favorite?Will any of these pique his curiosity?Will his giant head blow up from too many theories?What are these twelve theories, and do any of these have any merit? Follow me on Instagram @masonicmuscleTikTok @Masonicmsucle357Write to me at Masonicmsucle357@gmail.com

7-7 Dirty Work Hour 2: Joey Chestnut reigns supreme & the latest on a potential GS-SAC Kuminga tradeSee omnystudio.com/listener for privacy information.

President Trump achieved significant victories at the Supreme Court during its most recent term. Perhaps the biggest was when the Court limited the power of federal judges and their use of nationwide injunctions. The Trump administration has argued that lower courts were abusing their power and using injunctions to halt parts of the administration's agenda, including President Trump's executive order on birthright citizenship. Former federal prosecutor Jim Trusty recently joined FOX News Rundown host Dave Anthony to discuss the significance of this ruling and how it could impact the Democrats' efforts to slow or stop some of President Trump's policies. Trusty also weighed in on President Trump's deportation policies and the likelihood that the High Court would support President Trump's effort to end birthright citizenship for children of people who entered the country illegally. We often must cut interviews short during the week, but we thought you might like to hear the full interview. Today on Fox News Rundown Extra, we will share our entire interview with former prosecutor Jim Trusty about the Supreme Court's recent historic ruling and what it means for President Trump's agenda. Learn more about your ad choices. Visit podcastchoices.com/adchoices

President Trump achieved significant victories at the Supreme Court during its most recent term. Perhaps the biggest was when the Court limited the power of federal judges and their use of nationwide injunctions. The Trump administration has argued that lower courts were abusing their power and using injunctions to halt parts of the administration's agenda, including President Trump's executive order on birthright citizenship. Former federal prosecutor Jim Trusty recently joined FOX News Rundown host Dave Anthony to discuss the significance of this ruling and how it could impact the Democrats' efforts to slow or stop some of President Trump's policies. Trusty also weighed in on President Trump's deportation policies and the likelihood that the High Court would support President Trump's effort to end birthright citizenship for children of people who entered the country illegally. We often must cut interviews short during the week, but we thought you might like to hear the full interview. Today on Fox News Rundown Extra, we will share our entire interview with former prosecutor Jim Trusty about the Supreme Court's recent historic ruling and what it means for President Trump's agenda. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Federal Judge Brian Murphy—the unelected, black-robed, tyrannical, inferior federal district trial court judge raised to the federal bench on December 6, 2024, a FULL MONTH AFTER the re-election of President Donald J. Trump, was a mere 200 days on the bench when he had the dubious honor to be checked by the US Supreme Court itself on June 24 of this year, when SCOTUS paused the injunction Judge Murphy had issued against Trump's efforts to deport murderers and other violent illegal migrants from our great nation.That SCOTUS check didn't even give Judge Murphy pause, however, as the SAME DAY he issued an order informing the White House that the SCOTUS ruling against him nevertheless left him with the authority to order about the President in the exercise of his core and plenary Article III Executive Branch authority as if Trump were a mere clerk in Judge Murphy's court.Naturally, Trump immediately appealed this lawless judge's order right back to the Supreme court.A mere 9 days later, yesterday, July 3, 2025, SCOTUS was obliged to issue a rare “clarification” of its June 24 order against Judge Murphy, explaining as if to an idiot that their ruling against him was COMPREHENSIVE, and not something around which a judge on the federal bench for a mere 209 days was free to wiggle around. Join me LIVE as I break all this down into plain English, and explain what SHOULD be the consequence for unelected, black-robed, tyrannical, inferior federal court judge demonstrates such a psychotic intent to unlawfully constrain our elected Article II Executive Branch president in carrying out the will of the American people. Get Your FREE Copy of Our Best-Selling Book: "The Law of Self Defense: Principles"Visit Here: https://lawofselfdefense.com/getthebook"You are wise to buy this material. I hope you watch it, internalize it, and keep it to the forefront whenever you even think of reaching for a gun"-Massad Ayoob (President of the Second Amendment Foundation) The #1 guide for understanding when using force to protect yourself is legal. Now yours for FREE! Just pay the S&H for us to get it to you.➡️ Carry with confidence, knowing you are protected from predators AND predatory prosecutors➡️ Correct the common myths you may think are true but get people in trouble​➡️ Know you're getting the best with this abridged version of our best-selling 5-star Amazon-rated book that has been praised by many (including self-defense legends!) for its easy, entertaining, and informative style.​➡️ Many interesting, if sometimes heart-wrenching, true-life examplesGet Your Free Book: https://lawofselfdefense.com/getthebook

The truth is, we can't stop being sheep. We are naturally inclined to follow a higher authority. So how can I navigate the terrain of spiritual life without being manipulated or used? How can I see the wolves for what they are, and how can I find a proper shepherd? Today we discuss the concept of “sheep” and “wolves” in both societal and spiritual contexts. We explore the natural human tendency to follow leaders and the risks that come with it. You'll hear how according to the Vedas, a qualified spiritual guide is essential—but we are surrounded by deceptive leaders or “wolves in sheep's clothing”. Manipulation occurs in politics, media, and even spiritual communities. And so we need to develop a sincere, cautious discernment rather than blind acceptance. True spiritual teachers never exploit, as they are genuinely fulfilled and act only out of care. And a genuine follower remains humble, always seeking guidance rather than striving for independence or superiority. Ultimately, what we need is to cultivate awareness, deepen our connection to the Supreme, and rely on authentic sources of wisdom and inner guidance to avoid being misled. Highlights: (1:02) “What the great man does, the common man follows” (11:39) Manipulation within spiritual communities (19:33) Behind the candy coated talks, there's really an agenda (27:04) Without a teacher, you can't grow strong enough to resist being manipulated (36:50) We really can't be independent (42:00) A true teacher doesn't teach a sectarian belief system, he teaches the Absolute Truth Recorded on May 23, 2022. https://linktr.ee/breakingtrail

In this episode, Dan Hugger speaks with Marcel van Hattem, a Brazilian politician, journalist, and political scientist who is an elected federal representative of the State of Rio Grande do Sul in Brasilia. They begin by discussing Brazil's history, people, and culture. The conversation then turns to the ongoing constitutional crises and how the Supreme […]

In just seven short years, Charaf Tajer, the founder and creative director of the brand Casablanca, has proven that the fashion world has room for a multitude of sartorial expressions. His unique blend of old-money style, colorful prints, sporty inspirations and architectural touches has managed to recalibrate the language of contemporary fashion. With roots in Paris and Morocco, Charaf's path to fashion wasn't linear. He cut his teeth in the nightlife scene as the art director of Paris' iconic venue Le Pompon, but was also a creative consultant for Supreme, once upon a time collaborated with Virgil Abloh. But was also a co-founder of the streetwear brand Pigalle before launching Casablanca in 2018. A label born not from trend-chasing, but from a desire to distil elegance, memory, and escapism into clothing. Casablanca isn't just a fashion brand; it's a sensibility. A world where terry cloth tailoring meets Art Deco curves, and where every collection feels like a postcard from a sun-drenched far-flung destination. But behind the silk shirts and saturated palettes lies a precise vision – one that blends nostalgia with modernity and elevates leisurewear into a refined statement of intent. Now, the brand is entering a new era. With two flagship stores about to open – one in Paris and another in Los Angeles – Charaf is bringing his universe into physical form. It's a bold move, but then again, Casablanca was never about playing it safe. As you'll hear, Charaf is a designer who leads with instinct, impeccable craftsmanship, and a sociological eye.

Thank you, everyone, for participating in our special prayer for peace all over the world. This is an ancient process of meditation on the Supreme, called Kṛṣṇa. 'Hare' means the energy of the Lord. 'Kṛṣṇa' means the Supreme Personality of Godhead. And 'Rāma' means the highest pleasure. In this world, there are many anxieties that come to the mind. In the process of mantra, "man" means mind, and "tra" means to deliver. So, one chants the transcendental mantra that delivers the mind from all the anxieties that come from participating in the harried world of today. So, we invite everyone to chant along. There are some cards here with the mantra on them. You can take one with you, chant it in the shower or on your way to work, and you'll find that your mind will rise above the normal churnings that it goes through every day. And as it's stated in the ancient scripture, Śrīmad-Bhāgavatam, "vāsudeve bhagavati bhakti-yogaḥ prayojitaḥ janayaty āśu vairāgyaṁ jñānaṁ ca yad ahaitukam" (SB 1.2.7). When one performs transcendental divine service to the Supreme, Kṛṣṇa, then one automatically gets knowledge and detachment from the world. Those are hard to come by, so we invite everyone to chant along with us, and also never miss a chance to dance. There's not enough dancing in the world. ------------------------------------------------------------ To connect with His Grace Vaiśeṣika Dāsa, please visit https://www.fanthespark.com/next-steps/ask-vaisesika-dasa/ ------------------------------------------------------------ Add to your wisdom literature collection: https://iskconsv.com/book-store/ https://www.bbtacademic.com/books/ https://thefourquestionsbook.com/ ------------------------------------------------------------ Join us live on Facebook: https://www.facebook.com/FanTheSpark/ Podcasts: https://podcasts.apple.com/us/podcast/sound-bhakti/id1132423868 For the latest videos, subscribe https://www.youtube.com/@FanTheSpark For the latest in SoundCloud: https://soundcloud.com/fan-the-spark ------------------------------------------------------------ #kirtan #spiritualsongs #spiritualmusic #spiritualawakening #soul #spiritualexperience #spiritualpurposeoflife #spiritualgrowthlessons #secretsofspirituality #vaisesikaprabhu #vaisesikadasa #vaisesikaprabhulectures #spirituality #bhaktiyoga #krishna #spiritualpurposeoflife #krishnaspirituality #spiritualusachannel #whybhaktiisimportant #whyspiritualityisimportant #vaisesika #spiritualconnection #thepowerofspiritualstudy #selfrealization #spirituallectures #spiritualstudy #spiritualquestions #spiritualquestionsanswered #trendingspiritualtopics #fanthespark #spiritualpowerofmeditation #spiritualteachersonyoutube #spiritualhabits #spiritualclarity #bhagavadgita #srimadbhagavatam #spiritualbeings #kttvg #keepthetranscendentalvibrationgoing #spiritualpurpose

READ: https://www.judicialwatch.org/biden-fisa-spying-trump/READ: https://www.judicialwatch.org/trump-disinformation-purveyors/READ: https://www.judicialwatch.org/collusion-docs-jack-smith-operation/READ: https://www.supremecourt.gov/opinions/slipopinion/24SUPPORT OUR WORK https://www.judicialwatch.org/donate/thank-youtube/ VISIT OUR WEBSITE http://www.judicialwatch.org

Federal court judges just got a major wake-up call—and so did the left’s interpretation of birthright citizenship—as a powerful new ruling shakes the legal landscape. It’s a HUGE win for President Trump… and Letitia James and AOC are furious. Meanwhile, Letitia James could be on the verge of losing her re-election bid in New York, and Rep. Elise Stefanik is stepping in to take on Kathy Hochul in the governor’s race. Plus, former MSNBC host Joy Reid embarrasses herself on CNN in a wild segment, and even top Democrats like Adam Schiff and Rahm Emanuel are now praising Trump’s Iran strategy. The tide is turning—and the left knows it. #news #SupremeCourt #Trish SUBSCRIBE TO MY CHANNEL: https://Youtube.com/TrishReganChannel Become a TEAM MEMBER to get special access and perks: ▶️ https://www.youtube.com/channel/UCBlMo25WDUKJNQ7G8sAk4Zw/join

Howie Kurtz on GOP Senators in rural states pushing back on slashing Medicaid spending in 'big beautiful' bill, Trump threatening to suspend military aid to Israel if Netanyahu's prosecution isn't stopped and Trump getting a series of wins in Supreme court cases. Follow Howie on Twitter: ⁠⁠⁠@HowardKurtz⁠⁠ ⁠⁠For more #MediaBuzz click here Learn more about your ad choices. Visit podcastchoices.com/adchoices

Bob is back from vacation, fired up and ready to go. Bob kicks things off talking with Congressman Jim Jordan. They discuss the Big Beautiful Bill, and the big Supreme Court wins for President Trump last week. Bob then welcomes Rep Josh Williams to talk about his run for congress and taking on Marcie Kaptur. Bob then talks about the Supreme court and the possibility of a communist mayor in New York.See omnystudio.com/listener for privacy information.

Kim St. Onge hosts the Marc Cox Morning Show and talks with Scott Jagow about the Senate's 51 to 49 vote on Donald Trump's “Big, beautiful bill.” They unpack the vote-a-rama process and what's next in the House. The Supreme Court takes center stage with rulings on LGBTQ education opt-outs, nationwide injunctions, and age verification for online adult content. The segment also explores the origins of the Fourth of July and hot dog eating contests. Scott weighs in on New York City's mayoral race, where Zohran Mamdani's democratic socialist platform is drawing national attention.

How we know God impacts the way we live in Him, bear fruit for Him and grow in Him.

The left is the establishment now no matter what the liberal media tries to say. New Yorkers are scared at a Zohran administration as NYC mayor and the media is pulling the race card as the reason. The Supreme court makes a historical decision on Trump's birthright executive order and James T. and Producer Aaron pray after a murder plot in a 5th grade Surprise, AZ school was uncovered. Finally, the Conservative Circus says goodbye to Producer Bannon, aka, Young BC.

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

The Supreme court has come out with some key rulings today, one involving President Trump's birthright citizenship...we talked to KTAR legal analyst Barry Markson to give it some clarity.

Former US Attorney Jim Santelle takes us through a flurry of US Supreme Court opinions being issued in the final days of their session—some of which reaffirm how extreme the right wing justices are taking American law. And our Week In Review panel looks at how the Trump White House wants those pesky reporters to focus the big bombs used against Iran and not on whether the attack actually worked. Mornings with Pat Kreitlow is powered by UpNorthNews, and it airs on several stations across the Civic Media radio network, Monday through Friday from 6-9 am. Subscribe to the podcast to be sure not to miss out on a single episode! To learn more about the show and all of the programming across the Civic Media network, head over to civicmedia.us/shows to see the entire broadcast line up. Follow the show on Facebook, X, and YouTube. Guests: Jim Santelle, Mark Jacob, Jennifer Schulze

Deb and Tyler Find Out Who Reigns Supreme in Can't Beat Deb!See omnystudio.com/listener for privacy information.

US Secretary of Defence Pete Hegseth holds morning newser, insisting strikes dealt a severe blow to Iranian nuclear sites. Iran's Supreme leader congratulates nation for victory over Israel in first public appearance since ceasefire. 3 Palestinian men killed by Israeli settlers who attacked and set fire to their community near Ramallah. Mexico's top court orders release of case file on 43 missing Ayotzinapa students. Prime Minister Mark Carney's major projects bill C5 could pass in the Senate as early as today. Americans reflect on 10 years since the United States legalized same-sex marriage. Buskers in Quebec City slam a new rule requiring they sing in French only.

DMA STINGY (0:14) 2020 BLM PROTEST (02:30) STREAMER U (05:45)  AI TAKEOVER (10:09) YE MAKING N*ZI NORMAL (16:08) BREEZY AT BADDIES (24:48) KID CUDI VS THUG (30:27) BREZY X DRUSKI (34:39) GET IT OFF YA CHEST (41:30)Ft  @Breezyxsupreme ​LEAVE US A RATING!!!!!!Follow our mains on IG@IAMNAS_YKT@sirmisterbizz @DmaGotDaJuice Audio Mixed by @dmagotdajuiceNothing But Discussion Social's!!!https://instagram.com/nothingbutdiscussion?igshid=YmMyMTA2M2Y=Twitter: https://twitter.com/nothingbutdisc1

The following political analysis is from Business-Industry Political Action Committee (BIPAC) Senior Political Analyst Jim Ellis.  BIPAC is an independent, bipartisan organization.  It is provided solely as a membership benefit to the organization's 200-plus member companies and trade associations.  The views and opinions expressed do not necessarily represent those of any particular member or organization.

Subscribe to the paper: https://simplecirc.com/subscribe/17820213Don't miss the extra story! Become a supporter at: https://catholicfamilynews.locals.comAngelico: https://collabs.shop/7mq5ifShow Notes: Weekly News Roundup June 25th, 2025 - Catholic Family NewsJoin Brian McCall and Murray Rundus as they discuss this week's storiesCrisis in Iran averted?Supreme court and immigrationPope Leo XIV updateTLM crisis in TulsaDon't miss the extra story! Become a supporter at: https://catholicfamilynews.locals.comCulture:Follow us on Rumble! https://rumble.com/c/c-390435#catholic #catholicchurch #christianity

This week, Aliyar Hajinabi from the Polaris Supreme stops by the studio to chat about how fishing is going this year, bluefin fishing and everything in between. Join CCA: www.JoinCCA.orgVisit us: www.CCACalifornia.org

Dr. Powers joins the show for Where Past Meets Present, the founding of Grants Pass today and a talk on the Supreme court cases happening. Kevin Starrett calls from Oregon firearms...looking for some help to get the gun bills killed.

Sensing the Supreme Holiness of the Almighty God; Isaiah 6:1-13; David Harl. Scripture read by Roderick Vaughn.

After 2 missile strikes this morning, Israeli Prime Minister Benjamin Netanyahu is vowing "The Full Price" from the dictators in Tehran. A big win for those who oppose transgender procedures on young people. The U.S. Supreme court upheld ...

After 2 missile strikes this morning, Israeli Prime Minister Benjamin Netanyahu is vowing "The Full Price" from the dictators in Tehran. A big win for those who oppose transgender procedures on young people. The U.S. Supreme court upheld ...

After 2 missile strikes this morning, Israeli Prime Minister Benjamin Netanyahu is vowing "The Full Price" from the dictators in Tehran. A big win for those who oppose transgender procedures on young people. The U.S. Supreme court upheld ...

After 2 missile strikes this morning, Israeli Prime Minister Benjamin Netanyahu is vowing "The Full Price" from the dictators in Tehran. A big win for those who oppose transgender procedures on young people. The U.S. Supreme court upheld ...

After 2 missile strikes this morning, Israeli Prime Minister Benjamin Netanyahu is vowing "The Full Price" from the dictators in Tehran. A big win for those who oppose transgender procedures on young people. The U.S. Supreme court upheld ...

Lawmakers on both sides urge President Trump not to enter the Israel-Iran war. The Supreme deals the transgender community a major blow by upholding a Tennessee law.

AP correspondent Charles de Ledesma reports on Iran's missiles hitting sites in Israel; Israel's defense minister says Iran's Supreme leader should die; and hackers with possible links to Israel drain more than $90 million from Iran's largest cryptocurrency exchange.

AI may be fast, smart, and shockingly efficient. But is it truly intelligent? In this thought-provoking solo episode, I explore a powerful and timely idea: the future belongs to those who change the game entirely, not those who keep trying to outrun AI at what it does best. Freelancers and creative professionals are feeling the pressure. AI can now write emails, analyze data, and churn out decent content in seconds. But there's something artificial intelligence can't do: think, discern, feel, and create the way you can. I introduce the concept of “meta-talents” — the higher-order human skills that AI can't replicate — and explain how freelancers can leverage them as a unique competitive edge. What You'll Learn Why AI is making mediocrity obsolete... and what that means for your freelance business The difference between pattern-matching intelligence and true human discernment A breakdown of the 7 meta-talents that set you apart (and why they matter more than ever) How to integrate AI tools strategically without losing your voice or value A practical approach for using AI as a creative amplifier, not a replacement Key Insights and Takeaways AI isn't your competition; it's your complement AI excels at narrow, pattern-based tasks. But it lacks judgment, taste, empathy, and original thought. That's your domain. Your meta-talents are your unfair advantage These include: Taste – Recognizing quality and nuance Discernment – Knowing what matters and why Curation – Synthesizing the best of the best Point of View – Expressing what only you can say Strategic Decision-Making – Choosing wisely amid uncertainty Emotional Intelligence – Reading people and context Pattern-Breaking – Innovating beyond the obvious Writer A vs. Writer B Both use AI, but Writer B asks better questions, brings unique experience to the table, and produces content that's unmistakably human. That's the kind of work clients will still pay premium fees for. Use AI for scaffolding, not soul Let AI handle the grunt work so you can focus on insight, creativity, and strategy. In other words, the things it can't do. This isn't about efficiency. It's about amplification. Action Steps You Can Take This Week Conduct a “Meta-Talent Audit” Which of the seven meta-talents do you lean into most? Which ones need development? Try the “Discernment Challenge.” Use AI to generate options (e.g., headlines or content ideas) Then ask: Which ones truly fit this audience at this moment? Why? Reframe your use of AI Next time you use a tool like ChatGPT, don't just accept the output. Ask: What would make this mine? Where can I add taste, voice, or nuance? Start building your POV Journal daily to explore your thinking, beliefs, values, and unique insights. Ask: What do I see that others don't? Memorable Soundbites “AI can suggest. But it can't discern.” “Use AI for scaffolding—not soul.” “The future belongs to those who pair their meta-talents with smart tools.” “AI doesn't make you replaceable. It makes you irreplaceable—if you let it.” Listener Challenge This week, block off 30 minutes and reflect: What's your unique value that no AI can replicate? How are you developing and showcasing that? What's one small action you can take to lean into your meta-talents? Start now, because the era of “good enough” is over. And your human edge has never been more powerful. If this episode resonated with you, share it with a fellow freelancer who's navigating the evolving AI landscape. And don't forget to subscribe so you never miss an episode packed with insights to help you earn more in less time… doing work you love.

Déjà vu in the Matrix films signified a change in the simulation, when something was reset. This is exactly how it feels when watching and listening to news this week: WMDs have become “Iran cannot have a nuclear bomb,” and Bush's “you are either with us, or with the terrorists” has become Netanyahu's “it's either us or them.” It's all broadcast via programing through television (Zion) and social media, as in the enchantress Medea in Greek mythology. The enchantress enchants, which means reciting an incantation like “Israel has a right to defend itself.” This repetition of these incantations is a spell that programs the mind-set within the head-temple, which produces the zealotry we see. Accusations of the “WMD” need no proof, because the culture is saturated with so much anti-Islam, anti-Arab, and truly anti-semitic propaganda that accusation is evidence enough of guilt. Tulsi Gabbard, director of National Intelligence, and American spies, all deny Iran has a bomb, yet the President ignores this. It's similar to the historic witch hunt with the accused only being freed upon death, the only proof of innocence. This underlying occult motif is also amplified by the Afghanistan, Iraq, Syria, and Libya wars being aligned with Jewish holy days, with Iran on June 13 aligning with the 613 Mtizvot and both Friday 13 and the witching hour. Now we approach the summer solstice and the three week period of jewish mourning for the destruction of their temple and exile. Fear of the bomb itself, with threats to evacuate Tehran or Tel Aviv, or even an American city, instills as much terror as the “shock and awe” of Iraq. The most interesting possibility might be that Israel, not Iran, threatened to assassinate the President, and that if Iran did have a bomb, that Israel has been lying about their intentions to use it for decades, while they conceal their own program as part of a conspiracy, along with their psychotic Samson option to destroy the world. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKYOUTUBEMAIN WEBSITECashApp: $rdgable Paypal email rdgable1991@gmail.comEMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Subscribe to Throwing Fits on Substack. It's not clocking to you that we're standing on business, is it? This week, Jimmy and Larry want to thank everyone for buying shorts for a good cause, set your calendar alerts because we're doing a live pod at ThriftCon this weekend—Saturday, June 21st—jeans that are definitely jeans, when the brand doubles as your zodiac sign, Très Bien's sale is not to be trifled with, did we finally learn how to pronounce Port Tanger, we're not saying we convinced John C. Reilly to join Instagram but maybe we did, Tennis has officially gone full streetwear thanks to Supreme x Yonex and Kith x Wilson so how did we get here and what does it mean, are there any hobbies left that are immune to collabs, Lawrence had a wonderful time dining at Eddie Huang's new pop-up restaurant Gazebo, Asian fusion is so back which is good because it rules, James mingles with the fairer sex at Paige DeSorbo's Daphne launch, pajama drama, welcome to Jamaica where the Red Stripe is frosty and the fire is slapped, it's WW3 so make sure you hit up the gay orgy bomb shelter, explaining why Quentin Tarantino and Caitlyn Jenner are in Israel, England is magic, buying stock in a new TikTok guy, revising our assessment of Justin Bieber's mental health and more.

This week the gang talked about all the SGF shows, Chess Hunt, OPTCG 2v2, Bravely Default Flying Fairy HD Remaster, and more!Follow us on Instagram Leave us a voicemail at (804) 286-0626 and consider supporting us through our Patreon Check out the Discord! News Links:Summer Games Fest RE9 preview Xbox Showcase Tango is back! 

Busy Weekend: No Kings protests, Army 250th Anniversary Parade, Israel v. Iran, and Minnesota lawmakers murdered. PLUS- Eli Zaret joins us, Antonio Brown wanted for attempted murder, Meghan Markle makes Father's Day about Harry, Justin Bieber's breakdown, and Paris Jackson v. critics. Tom Mazawey and Drew lost their bowling matchup with Gibby. Eli Zaret dropped by today to bore us with golf stories from the US Open, Tiger Woods commercials, the Detroit Tigers drop a series to the Cincinnati Reds, Rafael Devers traded to San Francisco Giants, Tarik Skubal's contract options, the terrible Colorado Rockies, Shohei Ohtani is back pitching, update us on the NBA Finals, the NHL Stanley Cup Finals, Antonio Brown's attempted murder charge, Chris Webber allegations, Jimmie Ward accusations, a Tom Brady statue, Surviving Ohio State, stupid WNBA records, MSU's new Athletic Director, Joey Chestnut is back and more. Congrats to ______________ for winning the Legacy Partner's gift card. Meghan Markle gave tribute to only 1 of the 3 fathers in her life. Brooke Shields hates Meghan Markle. Employees are leaving left and right. Justin Bieber is popping off again. He's so badass. He needs a conservatorship. Marc burned his nutsack this past weekend. Nezza prefers the National Anthem in Spanish and not listing to the Los Angeles Dodgers. Skinny Chad has entered the Dabbleverse. We check out THREE different speeches by crybaby Brendan Fraser. Israel and Iran are bombing each other. The No Kings protest is protesting the apparent King of the United States of America. A protestor in Salt Lake City was killed. ICE protests roll on. Donald Trump's military parade was a dud. Is the Trump Unity Bridge dismantled? We call Rob Cortis to get to the bottom of the rattletrap controversy. Kim Adams is battling health issues. Diddy is still looking for a mistrial thanks to ‘Juror 6'. Another juror got an odd message. Happy Father's Day to Diddy. Minnesota lawmakers murdered. Vance Boelter arrested. Drew declares Vance thinks himself hot. Paris Jackson vs Michael Jackson fans. Hey Lara Flynn Boyle… do you look different or not? Jessica Alba hates Cash Warren. Diane Sawyer is back as she interviews Eric Dane about his ALS diagnosis. Matthew Perry's doctor pleads guilty. Meghan Markel defends her pregnant dance by touting its “authenticity”. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

Achyutam Keshavam Krishna Damodaram, Ram Narayanam Janaki Vallabham (Verse 1) Yo, the Vrndavana forest, from rains it improved, With dates, mangoes, and blackberries, all sweetly approved. Lord Krishna, the Supreme, with His boyfriends so grand, And Balarama too, they strolled through the land. The cows, filled with new grass, so healthy and fat, Their milk […] The post Song: Rainy Season in Vrndavan appeared first on Radha Krishna Temple in Utah.

John is joined by journalist Karen Hao to discuss her new book, “Empire of AI: Dreams and Nightmares in Sam Altman's OpenAI,” and both the promise and the perils of the coming age of artificial intelligence. Hao explains how OpenAI went from being an altruistic nonprofit dedicated to ensuring that A.I. would “benefit all of humanity” to a burgeoning commercial colossus valued at north of $300 billion; how Altman wrested control of the company from his co-founder Elon Musk; why skepticism is warranted regarding the claims that superhuman A.I. is inevitable; and how that narrative, true or not, serves the economic and political interests of the cabal of tech bros who are A.I.'s most fervent boosters. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

You need to put things into perspective and take control of your life. Nobody cares about a Supreme backpack when your health isn't going anywhere... Stop caring and stressing about dumb shit and look at what's important.